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Cardio-Oncology: The Role of 
Echocardiography in Cancer 
Patients
Theodoros Ntoskas
Abstract
Cardio-oncology is a rapidly emerging medical field that focusses on the 
improvement of the quality of life of cancer patients by preventing and treating the 
adverse cardiovascular complications of cancer therapy. Early recognition of cancer 
therapy-related cardiac dysfunction (CTRCD) provides an opportunity to mitigate 
cardiac injury and risk of developing late cardiac events. Cardiac imaging, and in 
particular, transthoracic echocardiography, plays an essential role in the baseline 
assessment, the detection and the surveillance of CRTCD in patients during and 
after the cancer therapy. Although the frequency of screening for the cardiotoxic-
ity in patients undergoing active treatments and cancer survivors remains a topic 
of debate and ongoing research, echocardiography continues to be the leader for 
continuous monitoring by imaging due to the wide availability, lack of exposure 
to radiation, ability to recognise the effects on cardiac function and assess hae-
modynamics and other cardiac structures. The cardiac imaging applied to cardio-
oncology includes standard and advanced (speckle tracking and three-dimensional 
(3D)) echocardiography.
Keywords: cardio-oncology, echocardiography, cancer, cardiotoxicity, heart failure, 
global longitudinal strain
1. Introduction
Advances in treatment have led to improved survival of patients with cancer 
but have also increased morbidity and mortality due to treatment side effects [1, 2]. 
Chemotherapy and radiation therapy can put patients at risk for a variety of cardio-
vascular complications including heart failure, coronary artery disease, peripheral 
vascular disease, thromboembolism, pericardial disease and valvular heart disease. 
Cardiovascular disease is now the second leading cause of morbidity and mortality 
in cancer survivors [3]. Cancer patients receiving therapy with known cardiac risk 
require close monitoring during and after treatment. In current cardio-oncology 
practice, echocardiography is the most widely used technique in the diagnosis, 
prevention and risk stratification of CTRCD in patients during and after cancer 
therapy. The utility of the advanced echocardiography is emerging as the three-
dimensional echocardiography derived left ventricular ejection fraction (LVEF) 
has an excellent correlation with cardiac magnetic resonance imaging and can be 
used to monitor LVEF and the two-dimensional speckle tracking echocardiography 
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(2D-STE) derived strain and strain rate can detect changes in myocardial mechan-
ics before changes in LVEF occur.
2. Cardiovascular complications of cancer therapy
Cancer treatment can cause various types of cardiovascular (CV) complica-
tions. Different cancer therapies have different CV complications. Cancer therapy 
toxicity is related to the mechanism of action of the drugs, the doses, the manner 
of administration and the underlying predisposing factors such as cardiac condi-
tions, genetic pattern and age, and it can manifest itself immediately or many years 
after the treatment. Table 1 summarises a variety of anti-cancer therapies and their 
associated complications, including myocardial dysfunction, heart failure, coro-
nary artery disease, valvular heart disease, arrhythmias, hypertension, peripheral 
vascular disease, stroke and pulmonary hypertension [4].
Echocardiography is a non-invasive method that can perform a comprehensive 
evaluation in all stages of cancer treatment and detect myocardial, coronary, valve, 
pulmonary hypertension and pericardial disease complications secondary to the 
therapeutic regimen used (radiotherapy and/or chemotherapy).
3. Definition of CTRCD
Myocardial dysfunction and heart failure are the most concerning cardiovascu-
lar complications of cancer therapies and cause an increase in morbidity and mor-
tality. Different definitions of CTRCD have been used historically [5]. Guidelines 
from cardiac societies [4, 6] define cardiotoxicity when the left ventricular (LV) 
ejection fraction (EF) falls to a value below the lower limit of normal (e.g. 53% in 
American Society of Echocardiography [ASE] guidelines) with more than a 10-per-
centage point reduction. As per the ESMO guidelines, the cut-off is 50% [7], at 
Cardiovascular toxicity Anti-cancer therapy
Myocardial dysfunction and 
heart failure
Anthracyclines (doxorubicin, idarubicin and epirubicin), anti-HER2 
(trastuzumab), VEGF inhibitors, cyclophosphamide, cisplatin, 
ifosfamide and taxanes (paclitaxel and docetaxel)
Vasospasm or vasoocclusion 
resulting in angina or myocardial 
infarction
Fluoropyrimidines (5-FU, capecitabine and gemcitabine), platinum 
compounds (cisplatin), VEGF inhibitors (bevacizumab, sorafenib and 
sunitinib) and radiotherapy
Valvular disease Radiotherapy
Arrhythmias Anthracyclines, histone deacetylase inhibitors, tyrosine kinase 
inhibitors (TKIs) (especially vandetanib high incidence of QT 
prolongation)
Arterial hypertension VEGF inhibitors
Peripheral vascular disease and 
stroke
Nilotinib, ponatinib or BCR-ABL tyrosine kinase inhibitors, 
radiotherapy. L-asparaginase, cisplatin, methotrexate, 5-FU and 
paclitaxel can cause Raynaud’s phenomenon
Pulmonary hypertension TKI (dasatinib), the TKI imatinib improved haemodynamics in 
patients with advanced pulmonary arterial hypertension
Abbreviations: HER2, human epidermal growth factor receptor 2; VEGF, vascular endothelial growth factor.
Table 1. 
Cancer drug agents associated with cardiovascular toxicity.
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which point cardio-protection should be considered [8]. ASE/European Association 
of Cardiovascular Imaging (EACVI) further classifies CRTCD into either those 
associated with anthracyclines or trastuzumab use. Anthracycline-related CRTCD 
is cumulative, dose dependent and often progressive and irreversible at cell level. 
On the other hand, trastuzumab-related CRTCD is dose independent, does not lead 
to cell death and is often reversible (Table 2).
4.  Cancer therapy-related cardiac dysfunction (CTRCD) and 
echocardiography
4.1 LV systolic function
The need for a timely diagnosis of subclinical and clinical heart failure by using 
cardiac imaging has been addressed by the Expert Consensus of the ASE and 
EACVI [6] and more recently reinforced by the ESC Position Paper on cancer treat-
ments and cardiovascular toxicity [4]. The quickest and most available imaging tool 
in detecting cancer therapy-related cardiac dysfunction (CTRCD) is transthoracic 
echocardiography.
Exposure to potentially cardiotoxic chemotherapeutic agents is a well-recog-
nised indication for baseline and longitudinal evaluation of LV function [9, 10]. The 
most commonly used parameter for monitoring LV function with echocardiography 
is LVEF. Traditionally, an echo determination of LVEF is requested by the oncolo-
gists in all cancer patients at baseline and in any situation in which the suspicion of 
heart failure is plausible, during and after completion of the anti-cancer therapy. 
2D-derived LVEF is also used to start cardio protection and to establish the inter-
ruption from anti-cancer therapies. The calculation of LVEF should be done with 
the best method available as per the skills and experience of the operators in a 
given echocardiography department. The same method needs to be maintained for 
surveillance during and after treatment. Importantly, the digital images obtained 
should be available for visually comparison with the previous studies and further 
discussion at multimodality echocardiographic and cardio-oncology team meet-
ings. According to joint recommendations from the ASE/EACVI, the method of 
choice for LV volume quantification and LVEF calculation is the modified biplane 
Type I Type II
Anti-cancer 
characteristic 
chemotherapy agents
Doxorubicin Trastuzumab
Clinical manifestation New onset of heart failure and LV 
systolic dysfunction
Asymptomatic decrease in LVEF 
and less often clinical heart failure
Dose effects Cumulative, dose dependent Not dose related
Clinical course May stabilise with heart failure therapy 
(ACE inhibitors and beta-blockers), but 
underlying myocyte destruction appears 
to be permanent and irreversible
Often reversible with treatment 
discontinuation (to or near 
baseline cardiac status in 
2–4 months)
Effect of rechallenge High probability of recurrent 
dysfunction that is progressive
Rechallenge is often tolerated after 
recovery
Abbreviation: ACE, angiotensin-converting enzyme; LV, left ventricle; EF, ejection fraction.
Table 2. 
Characteristics of type I and II cancer therapeutics-related cardiac dysfunction.
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Simpson’s technique by 2D echocardiography, with an LVEF of ≥55% as a normal 
reference range. Calculation of LVEF should be also combined with assessment 
of the wall motion score index, which is based on a 16-segment model of the left 
ventricle [11]. Resting wall motion score index based on a 16-segment model of the 
left ventricle has been demonstrated to be a more sensitive marker of anthracycline-
induced CTRCD than relying on the LVEF alone [12]. When two contiguous LV 
segments are not well visualised on non-contrast apical images, the use of myocar-
dial contrast agents is recommended [13].
Although LVEF is a commonly accepted measure of cardiac systolic function 
and an accepted indicator of prognosis in patients with heart failure [14], it has 
low sensitivity for the detection of small changes in LV function. LVEF measure-
ment using the 2D biplane technique has a temporal coefficient of variation of 
7.4% [15], which is important to highlight because the measurement variability is 
close to the definition of CRTCD (drop in LVEF of 10% or more). This variability 
is the result of a number of factors including the operator’s skills and the geometric 
assumptions used to estimate three-dimensional (3D) volumes from 2D images. 3D 
echocardiography has been shown to be more accurate than the 2D echocardiogra-
phy in the measurement of the LV volumes [16]. However, the feasibility of the 3D 
technique can be reduced in some cancer patients because of the negative influence 
of factors such as concomitant radiotherapy (breast cancer and lymphoma) and 
surgery (mastectomies of left breast cancer, breast expanders or implants), which 
makes the ultrasound windows under these circumstances suboptimal [17]. The 
ASE recommends 3D echocardiography as the preferred technique for monitoring 
LV function and detecting CRTCD. However, it is important to realise that this 
technology has several limitations as well. It is recommended that calculation of 
LVEF by 2D biplane Simpson’s method also be included in all the oncologic patients 
echocardiographic report to allow comparison with previous studies if this method 
was used.
To minimise the risk of irreversible cardiomyopathy, the goal is to identify signs 
of toxicity as early as possible. Echocardiography-based deformation imaging 
techniques (strain) have become an essential tool to detect CRTCD. Changes in 
strain are more sensitive, appear prior to LVEF reduction and before the CRTCD 
manifests as symptomatic heart failure. Global longitudinal strain (GLS) is of 
particular interest because it can be incorporated into a clinical echocardiographic 
examination relatively efficiently with currently available technology [18]. The 
EACVI and ASE recommend assessing GLS as a routine component of clinical 
echocardiograms in patients at risk for type 1 or type 2 cardiotoxicity [6]. A relative 
percentage decrease in GLS > 15% is indicative of subclinical LV dysfunction and 
could be utilised as the starting point for timely cardio protection therapy.
4.2 LV diastolic function
A comprehensive assessment of LV diastolic function, including grading of dia-
stolic function and providing an estimate of LV filling pressure (by using the E/e′ 
ratio), should be performed in addition to the assessment of LV systolic function 
[19]. Although abnormal diastolic function parameters may reflect subclinical LV 
dysfunction, it has not been found to be prognostic of cardiotoxicity, and its clinical 
significance remains uncertain.
4.3 Right ventricular (RV) function
The frequency of the RV dysfunction during cancer therapy-related cardio-
toxicity has not been accurately examined. As early studies of CRTCD included 
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RV biopsies, there is a suggestion that the RV is affected by cancer therapies [20]. 
However, the prognostic value of RV dysfunction at the time of cardiotoxicity 
warrants further investigation.
5. Coronary artery disease (CAD)
The diagnostic capability of rest echocardiography in CAD is limited to the 
assessment of the presence and magnitude of regional wall motion abnormalities.
Stress echocardiography, an established technique for the detection and prog-
nostication of stable CAD as recommended by guidelines, may be useful in the 
evaluation of patients who are undergoing regimens that may be associated with 
ischemia, as fluoropyrimidines, platinum compounds (cisplatin), vascular endothe-
lial growth factor inhibitors and radiotherapy.
Stress echocardiography is also being used to unmask subclinical abnormalities 
of the LV function induced by chemotherapeutic agents. Although both exercise 
[12] and dobutamine stress echocardiography [21–23] have been applied to patients 
with cancer for the identification of anthracycline-induced CTRCD, the results 
of these studies appear to be inconclusive and contradictory. Further studies are 
needed to better understand the prognostic role of stress echocardiography, before 
can be routinely used into clinical practice.
6. Valvular disease
Patients who have received radiation therapy are at risk of long-term cardiovas-
cular toxicity including radiation-induced heart valve disease, pericardial disease 
and coronary artery disease.
Transthoracic echocardiography is the main tool to identify valvular damage in 
these patients. There are distinct echocardiographic characteristics of radiotherapy-
induced valvular disease. The main distinguishing features between radiotherapy-
induced valvular heart disease and rheumatic heart disease are the presence of 
commissural fusion after radiotherapy, while the involvement of the mitral leaflet 
tips is an indication of rheumatic disease.
The EACVI and ASE expert consensus statement recommendations for long-
term follow-up after radiation therapy suggest a yearly physical examination to 
assess for symptoms or signs of radiation-induced heart disease, which if present 
should prompt further evaluation. In asymptomatic patients, a transthoracic 
echocardiogram is recommended 5 years after exposure in high-risk individuals 
and 10 years after exposure in all others [24]. High risk individuals are defined the 
patients who received anterior or left-side chest irradiation and have at least one 
additional risk factor (smoking, diabetes mellitus, hypertension, hyperlipidemia 
and obesity).
7. Pericardial disease
Pericardial disease in cancer patients is relatively common. Pericardial effusion, 
cardiac tamponade and pericarditis can appear during several types of chemo-
therapy (anthracyclines [25], cyclophosphamide [26] and cytarabine [27]) but are 
especially due to radiotherapy. Constrictive pericarditis is more often associated 
with radiation-induced cardiotoxicity [28]. Additionally, pericardial disease may be 
secondary to cardiac metastasis.
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Echocardiography is the first-line cardiac imaging for the diagnosis of cancer 
therapy-related pericarditis. It is useful for evaluating the degree of pericardial 
thickening, the presence of constrictive physiology and the presence and quanti-
fication of a pericardial effusion, as guidance of pericardiocentesis and for patient 
follow-up.
8. Conclusions
CV complications of cancer and its treatment have become increasingly recog-
nised as an important clinical issue, with the potential to cause acute complications 
during therapy. The field of cardio-oncology is relatively new but developing 
rapidly. The goal of this emerging subspecialty is to continue anti-cancer therapy 
without interruption, aiming at cancer cure and remission, or alternatively support 
the oncologist’s choice between different anti-cancer therapies, in order to maintain 
survival free from cardiovascular morbidity and mortality. In this context, standard 
and advanced echocardiography plays a pivotal role as the first-line imaging tool.
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